In its answer to the "Concept paper on pharmacovigilance implementing measures", the International Society of Drug Bulletins points out that the first and critical step in pharmacovigilance, namely the detection of safety signals, is left to pharmaceutical companies, despite their conflict of interest. Full transparency is key to avoid missing safety assessment opportunities. Read on...